- Research Fellowship - National Cancer Institute/NIH (2012-2013)
- Residency - University of North Carolina Hospitals (2015-2019), Radiation Oncology
- Internship - Santa Clara Valley Medical Center (2014-2015), Transitional Year
- Medical School - University of Michigan Medical School (2009-2014)
Dominic Moon, M.D.
- Radiation Oncology
- Head & Neck Cancers
- Skin Cancer
Dominic Moon, M.D., is an Assistant Professor of Radiation Oncology at UT Southwestern Medical Center specializing in the treatment of head and neck cancers, which includes cancers of the oropharynx, oral cavity, nasopharynx, larynx, paranasal sinuses, salivary glands, and skin.
Dr. Moon earned his medical degree at the University of Michigan Medical School. He also spent a year conducting clinical and translational research at the National Institutes of Health through the prestigious Medical Research Scholars Program during his time in medical school. He completed his residency training in radiation oncology at the University of North Carolina Hospitals where he served as Chief Resident.
He is passionate about delivering patient-focused multidisciplinary care to achieve optimal cancer and patient-reported outcomes.
Dr. Moon has authored or co-authored numerous research articles in prominent medical journals including JAMA Oncology, International Journal of Radiation Oncology, Biology, Physics, and Radiotherapy and Oncology.
Meet Dr. Moon
Dominic Moon, M.D., Assistant Professor in the Department of Radiation Oncology at UT Southwestern, developed an interest in the medical field as an undergraduate student volunteering at a cancer center.
“I got a glimpse of the difficulties and uncertainties patients face during their cancer treatments,” Dr. Moon says. “I also witnessed their incredible strength and resilience.” Once he decided to pursue a career in medicine, he always had the field of oncology in mind. “Radiation oncology was the best fit for me because it allows me to incorporate cutting-edge technology, build long-term relationships with patients, and cure their disease — or, if that's not possible, relieve suffering.”
Dr. Moon joins the department as a head and neck specialist. His interest in head and neck stems from the complex anatomy and the intricate relationship between the organs, nerves, blood vessels, and lymphatic system in this region.
Prior to joining UT Southwestern, his research focused on assessing patient-reported outcomes and toxicities related to cancer treatments, and this is something he would like to continue to explore. He plans to study ways to optimize radiation treatments to decrease side effects and improve patients’ quality of life.
Dr. Moon understands that a cancer diagnosis and its various therapy options are often quite overwhelming.
“My role as a physician and oncologist is not only to treat the cancer, but also to help patients understand the disease, the treatment plan, and ways to maximize their quality of life during and after treatment. We have a great team of clinicians, nurses, nutritionists, and speech and swallow specialists that work together to achieve these goals.”
- American Society for Radiation Oncology (ASTRO)
- American Society of Clinical Oncology (ASCO)
- J. Griswold and Margery H. Ruth Scholarship, University of Michigan Medical School 2009-2013
- Medical Research Scholars Program, National Institutes of Health 2012-2013
- Society for Translational Oncology Rising Star in Oncology 2018
- RSNA Roentgen Resident/Fellow Research Award 2019
- Pope Clinical Trainee Award, University of North Carolina 2019
Glioblastoma in Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide, 1st Ed.
Moon DH, Zagar TM (2018), Springer International Publishing
Secondary Malignant (Metastases) in Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide, 1st Ed.
Moon DH, Zagar TM (2018), Springer International Publishing
Ovarian Cancer in The Bethesda Handbook of Clinical Oncology, 4th Ed.
Lee J-M, Buckley de Meritens A, Moon DH, Kohn EC (2014), Philadelphia, Lippincott Williams & Wilkins
- Glioblastoma in Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide, 1st Ed.
Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose.
Wang K, Pearlstein KA, Moon DH, Mahbooba ZM, Deal AM, Wang Y, Sutton SR, Motley BB, Judy GD, Holmes JA, Sheets NC, Kasibhatla MS, Pacholke HD, Shen CJ, Zagar TM, Marks LB, Chera BS, JAMA oncology 2019 Feb 5 2 221-228
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC, British journal of cancer 2013 Aug 109 4 1072-8
Clinician-observed and patient-reported toxicities and their association with poor tolerance to therapy in older patients with head and neck or lung cancer treated with curative radiotherapy.
Moon DH, Chera BS, Deal AM, Wang Y, Muss HB, VanderWalde NA, Journal of geriatric oncology 2019 Jan 10 1 42-47
Comparison of Patient Report and Medical Records of Comorbidities: Results From a Population-Based Cohort of Patients With Prostate Cancer.
Ye F, Moon DH, Carpenter WR, Reeve BB, Usinger DS, Green RL, Spearman K, Sheets NC, Pearlstein KA, Lucero AR, Waddle MR, Godley PA, Chen RC, JAMA oncology 2017 Aug 3 8 1035-1042
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ Breast cancer research and treatment 2014 Aug 147 1 81-94
Partial Prostate Cancer Treatment for Aggressive Disease-Common Practice.
Moon DH, Chen RC, International journal of radiation oncology, biology, physics 2019 Aug 104 5 1035-1037
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O'Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ, Nanomedicine : nanotechnology, biology, and medicine 2019 06 18 189-195
Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
Moon DH, Basak RS, Usinger DS, Dickerson GA, Morris DE, Perman M, Lim M, Wibbelsman T, Chang J, Crawford Z, Broughman JR, Godley PA, Chen RC, European urology 2019 Sep 76 3 391-397
Shoulder symptoms and quality of life impact of limited neck dissection after de-intensified chemoradiotherapy: Secondary analysis of two prospective trials.
Wang K, Moon DH, Amdur RJ, Dagan R, Sheets NC, Shen CJ, Green R, Patel SN, Zanation AM, Thorp BD, Hackman TG, Weissler MC, Mendenhall WM, Chera BS, Head & neck 2019 May 41 5 1213-1219
Prospective assessment of patient-reported dry eye syndrome after whole brain radiation.
Wang K, Tobillo R, Mavroidis P, Pappafotis R, Pearlstein KA, Moon DH, Mahbooba ZM, Deal AM, Holmes JA, Sheets NC, Kasibhatla MS, Pacholke HD, Royce TJ, Weiner AA, Shen CJ, Zagar TM, Marks LB, Chera BS, International journal of radiation oncology, biology, physics 2019 Jul
Defining a Clinically Meaningful Benefit in Cancer Clinical Trials: From the Perspectives of the Clinical Trialist, Patient, and Society.
Moon DH, Chen RC, JNCI cancer spectrum 2018 Oct 2 4 pky039
A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy.
Moon DH, Wang AZ, Tepper JE, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018 Mar 126 3 527-533
What is the best way to radiate the prostate in 2016?
Moon DH, Efstathiou JA, Chen RC, Urologic oncology 2017 02 35 2 59-68
Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH, International journal of radiation oncology, biology, physics 2015 Apr 91 5 925-33
Radiation-induced intradural malignant peripheral nerve sheath tumor of the cauda equina with diffuse leptomeningeal metastasis.
Lau D, Moon DH, Park P, Hervey-Jumper S, McKeever PE, Orringer DA, Journal of neurosurgery. Spine 2014 Nov 21 5 719-26
Clinical indications for, and the future of, circulating tumor cells.
Moon DH, Lindsay DP, Hong S, Wang AZ, Advanced drug delivery reviews 2018 02 125 143-150
Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis.
Moon DH, Basak RS, Chen RC, Clinical genitourinary cancer 2017 Aug
Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers.
Moon DH, Moon SH, Wang K, Weissler MC, Hackman TG, Zanation AM, Thorp BD, Patel SN, Zevallos JP, Marks LB, Chera BS, Oral oncology 2017 09 72 98-103
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
O'Sullivan CC, Moon DH, Kohn EC, Lee JM, Frontiers in oncology 2014 4 42
- Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose.
- Investigation of patient-reported outcomes and toxicities related to radiation therapy
- Development of biomarkers to help assess response to therapy, guide treatment intensification or de-intensification, and detect early recurrence
- Combination strategies of radiation with systemic therapy including targeted therapy and immunotherapy
- Head & Neck Cancers
- Skin Cancer